التداخل بين أبريبيتانت وفينكريستين

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided.

Patients should be frequently monitored for adverse reactions with concomitant use of moderate CYP3A inhibitors (e.g., fluconazole) with vincristine sulfate.

Concurrent use of strong CYP3A inducers (e.g., St.

Intervention Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents Monitor for chemotherapeutic-related adverse reactions.